Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific Sessions

Salt Lake City, UT – July 13, 2025 – Microvascular Therapeutics (MVT), a pioneering Utah based biotechnology company, is thrilled to announce multiple accolades at the upcoming 36th Annual American Society of Echocardiography (ASE) Scientific Sessions, to be held September 5-7, 2025, in Nashville, Tennessee.

Abstract Accepted for Presentation

MVT’s groundbreaking abstract, Fibrin-Targeted Phase Shift Microbubbles for the Treatment of Myocardial Microvascular Obstruction: A Porcine Study, has been accepted for presentation at the ASE 2025 Scientific Sessions. The study, the result of a close collaboration between MVT and researchers at the University of Pittsburgh, Drs. Soheb Mohammed, Muhammad Amjad, Xucai Chen, and John J. Pacella, demonstrates the efficacy of MVT’s innovative sonoreperfusion therapy using fibrin-targeted phase-shift microbubbles (FTPSMBs). This image-guided ultrasound-activated microbubble cavitation  technique significantly enhances reperfusion in a porcine model of myocardial microvascular obstruction (MVO), a critical complication of acute myocardial infarction that lacks definitive treatment. The study highlights the potential of FTPSMBs to penetrate microthrombi and improve myocardial salvage, offering a promising new approach to significantly reducing life-threatening complications common after a heart attack.

Dr. Soheb Anwar Mohammed Honored as Top Investigator

The ASE Foundation has recognized Dr. Soheb Anwar Mohammed, Postdoctoral fellow at The University of Pittsburgh, as a Top Investigator for his exceptional contributions to the field. Selected for the scientific merit of his work on the MVT project, Dr. Mohammed will receive a $1,000 travel grant to support his attendance at the conference. This prestigious recognition underscores his role as a leading early-career researcher and the significance of MVT’s advancements in cardiovascular therapeutics. Dr. Mohammed will share his insights through social media during the event and provide a testimonial on how this support advances his professional goals.

Microvascular Therapeutics Selected for Shark Tank Innovation Competition

MVT has been selected to compete in the ASE 2025 Shark Tank Innovation Competition, a platform to showcase cutting-edge advancements in echocardiography and cardiovascular care. This invitation highlights MVT’s leadership in developing novel therapies, such as FTPSMBs, which promise to revolutionize the treatment of microvascular obstruction. The company looks forward to presenting its technology to a panel of experts and industry leaders, further solidifying its position at the forefront of medical innovation.

“We are honored by these recognitions from the ASE Foundation,” said Dr. Evan C. Unger, CEO of Microvascular Therapeutics. “Our team’s dedication to addressing unmet needs in cardiovascular care through sonoreperfusion therapy is reflected in these achievements. We are excited to share our progress with the global medical community in Nashville and to compete in the Shark Tank Innovation Competition.”

For more information about Microvascular Therapeutics and its innovative therapies, please visit www.mvtpharma.com.

Media Contact: Bryan Unger

Microvascular Therapeutics, LLC

1635 E. 18th Street, Tucson, AZ 85719

Email: b.unger@mvtpharma.com

Phone: (520) 555-1234

About Microvascular Therapeutics (MVT):Microvascular Therapeutics is a biotechnology company focused on developing next-generation microbubble-based therapies for cardiovascular and other diseases. Its proprietary fibrin-targeted phase-shift microbubbles (FTPSMBs) leverage ultrasound-targeted microbubble cavitation (UTMC) to address critical conditions such as myocardial microvascular obstruction, aiming to improve patient outcomes worldwide.

Investor Disclaimer: This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the potential efficacy and future development of Microvascular Therapeutics’ therapies, such as fibrin-targeted phase-shift microbubbles (FTPSMBs) and sonoreperfusion (SRP) therapy. These statements are based on current expectations and assumptions and are subject to significant risks and uncertainties that could cause actual results to differ materially from those anticipated. These risks include, but are not limited to, challenges in clinical development, regulatory approvals, market acceptance, and funding availability. Microvascular Therapeutics undertakes no obligation to update or revise any forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. For more detailed information on risks and uncertainties, please contact Microvascular Therapeutics directly.